https://www.selleckchem.com/pr....oducts/sodium-succin
An amendment to this paper has been published and can be accessed via a link at the top of the paper.Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide an overview of the current status of bispecific T cell engager (BiTE) therapy, considering the unprecedented new indication for such therapy in combating minimal (or measurable) residual disease in patients with acute lymphoblastic leukaemia, and the d
Like
Comment
Share
